ECRG4 and nasopharyngeal carcinoma: Further research revealed that ECRG4 was down-regulated to varying degrees in gastric cancer (14, 15), breast cancer (16, 17), hepatocellular cancer (18, 19), nasopharyngeal cancer (20–22), laryngeal cancer (23), bladder cancer (24, 25), glioma (26), colorectal cancer and prostate cancer (26–28).